Table 2.
Plasma Efavirenz Pharmacokinetics
| GM (95% CI) | ||||
|---|---|---|---|---|
| PK Parameter | PK1 | PK2 | PK3 | PK4 |
| Cmax, ng/mL | 2543 | 2549 | 3137 | 3232 |
| 95% CI | (1715–3602) | (1056–2443) | (1365–3405) | (1393–3802) |
| CV% | 73% | 75% | 81% | 82% |
| C18h, ng/mL | 1523 | 1148 | 1578 | 1838 |
| 95% CI | (967–2422) | (417–2276) | (997–2670) | (881–2739) |
| CV% | 63% | 37% | 66% | 73% |
| AUC0-18, ng*h/mL | 34,680 | 30,241 | 40,182 | 46,722 |
| 95% CI | (19,127–58,764) | (17,106–51,202) | (22,806–70,590) | (26,910–61,724) |
| CV% | 60% | 52% | 65% | 71% |
Note: Plasma efavirenz (EFV) pharmacokinetic (PK) parameters in HIV/TB co-infected patients given EFV 600mg for 2 weeks (PK1), 6 weeks (PK2), 20 weeks (PK3) and 48 weeks (PK4).
Abbreviations: AUC0-18, area under the concentration–time curve from 0 to 18 hours; C18h, 18-hour postdose concentration; CI, confidence interval; Cmax, maximum concentration; CV, coefficient of variation; GM, geometric mean; PK, pharmacokinetic.